Abstract
The percutaneous treatment of coronary bifurcation stenoses is hampered by an increased rate of subsequent restenosis. The present study reports on the outcomes of a consecutive series of 58 patients with 65 de novo bifurcation stenoses treated with sirolimus-eluting stent implantation in both the main vessel and side branch. At 6 months, the incidence of major adverse cardiac events was 10.3% (1 death and 5 target lesion revascularizations) with no episodes of acute myocardial infarction or stent thrombosis.
Publication types
-
Evaluation Study
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Angioplasty, Balloon, Coronary
-
Coronary Angiography
-
Coronary Artery Disease / diagnostic imaging
-
Coronary Artery Disease / drug therapy
-
Coronary Artery Disease / pathology
-
Coronary Artery Disease / therapy*
-
Coronary Restenosis / diagnostic imaging
-
Coronary Restenosis / mortality*
-
Coronary Restenosis / pathology
-
Female
-
Florida
-
Humans
-
Immunosuppressive Agents / administration & dosage*
-
Incidence
-
Male
-
Middle Aged
-
Registries
-
Sirolimus / administration & dosage*
-
Stents*
-
Treatment Outcome
Substances
-
Immunosuppressive Agents
-
Sirolimus